Tilray Brands (Nasdaq: $TLRY): Record FY2026 Revenue, FY2027 Guidance and Cannabis / Beverage Stock Hub

01 Latest verified update — cultivation capacity raised to about 275 tonnes, record FY2026 revenue and FY2027 guidance

Update through August 20, 2026 — Tilray announced an expansion of its global cannabis cultivation capacity to approximately 275 metric tonnes a year, up from approximately 210 metric tonnes, driven by expanded output at its Quebec facility in Canada and at its EU-GMP-certified facility in Portugal. Quebec capacity rose by 30 metric tonnes and the site is expected to reach EU-GMP certification within the next twelve months; the company is already shipping Quebec-grown bulk cannabis to its sites in Portugal and Australia. Output was also increased at the Portugal facility, which anchors supply to Germany and the United Kingdom, while in Germany the Aphria RX site is described as fully utilised, with the new ARX brand launched. The release carried no revenue, margin or capital-expenditure figure, so this is a capacity statement rather than a change already booked in the numbers. (Source: Tilray press release, August 20, 2026)

Update through July 29, 2026 — Tilray Brands reported fourth-quarter and full fiscal-year 2026 results on July 28, 2026 after market close, for the fiscal year ended May 31, 2026. The company delivered record annual net revenue of $915.5 million, up 11% from $821.3 million, and record adjusted EBITDA of $61.1 million, up from $55.0 million. Fourth-quarter net revenue was $281.7 million, up 25% year over year, with adjusted EBITDA of $31.9 million. Management stated that excluding approximately $2.3 million of fuel surcharges in the quarter, adjusted EBITDA would have been $63.4 million for the year and $34.2 million for the quarter. (Sources: Form 8-K, Exhibit 99.1 and FY2026 Form 10-K)

FY2027 guidance — for the fiscal year ending May 31, 2027 the company guided to adjusted EBITDA of $68 million to $75 million, which it described as double-digit growth versus fiscal 2026. In his prepared remarks, Chairman and CEO Irwin D. Simon said Tilray expects over $1 billion in annual revenue in fiscal 2027. That revenue statement is a management expectation, not a formally reconciled revenue guidance range: the only quantified guidance in the release is the adjusted EBITDA band.

Balance sheet — Tilray ended the fiscal year with approximately $234.6 million in cash, restricted cash and marketable securities and reduced net debt to $0.7 million. Cash and securities were lower than the $256.4 million held a year earlier, while the net debt position was materially larger at that time. Working capital was $433.8 million. The company also said cash flow from operations excluding working capital improved 157% to approximately $18.2 million. The GAAP number is less flattering and matters just as much: net cash used in operating activities was $69.1 million in fiscal 2026, an improvement from $94.6 million used in fiscal 2025, but still a cash outflow.

2027 convertible notes — the 10-K subsequent-events note states that after three private debt-for-equity exchanges between June 1 and June 24, 2026 — 3,852,527 shares issued against $18.0 million of principal — $70.0 million of principal remains outstanding on the 5.20% Convertible Senior Notes due June 15, 2027 as of the filing date. That is down from the $172.5 million originally issued in 2023, of which $84.5 million had already been settled by May 31, 2026.

Share count — the company had 131,683,075 shares issued and outstanding at May 31, 2026, compared with 106,067,875 a year earlier, and 136,203,579 shares as of July 24, 2026 per the 10-K cover page. Weighted average basic shares for the fiscal year were 111,832,375, up 26% year over year. The dilution is not theoretical: it is the mechanism through which much of the debt reduction and part of the acquisition strategy was funded.

New credit-agreement amendment — on July 24, 2026, subsidiary American Beverage Crafts Group entered into a Sixth Amendment to its credit agreement with Bank of America as administrative agent. Among other changes, the revolving commitments were reduced from $25.0 million to $15.0 million and certain financial covenants were modified. Management stated it does not anticipate breaching its financial covenants over the next fiscal year. A smaller revolver is a smaller emergency buffer, which puts more weight on operating cash generation.

U.S. rescheduling — in the release Tilray said it continues to evaluate multiple pathways into an emerging federally compliant, science-driven medical cannabis market, and that it has developed a blueprint for a U.S. Tilray Medical platform focused on research, education, cannabinoid-based medicine, patients and compliant medical access rather than adult-use retail. The company also stated that meaningful regulatory uncertainty remains, with ongoing legal challenges. No U.S. revenue from that blueprint is in the fiscal 2026 numbers or in the fiscal 2027 guidance.

Market context — $TLRY closed at $4.03 on July 28, 2026, before the release crossed the wire, after trading between $3.80 and $4.32 over the previous week. The full market reaction to the fiscal-year report falls into the July 29 session and beyond.

02 Previous update through July 24, 2026 — BrewDog not for sale, June debt exchanges and the completed hearing window

Update through July 24, 2026 — Tilray’s next scheduled company catalyst is its fourth-quarter and full fiscal-year 2026 report on Tuesday, July 28, after market close, followed by a 4:30 PM ET webcast. Investors should focus on the current share count, remaining 2027 debt, operating cash flow, adjusted EBITDA, beverage performance and the first fuller financial read-through from BrewDog.

BrewDog ownership status — James Watt publicly stated that his Second Best venture submitted an offer to acquire BrewDog. Tilray CEO Irwin Simon responded directly that BrewDog is “not for sale.” Through July 24, no signed agreement, accepted offer, SEC filing or Tilray transaction announcement confirms a sale. The correct classification is therefore an unsolicited approach that Tilray management has publicly rejected, not a pending or completed divestiture.

Operational confirmation — Tilray’s July 17 company release continued to describe BrewDog as owned by Tilray Brands and announced a £1 million bar-tab campaign at participating Tilray-owned BrewDog pubs from July 20 through September 30. This confirms continued ownership and operating activity, but the promotion itself is not evidence of financial success or a material earnings contribution.

DEA status — the announced hearing window ran from June 29 through July 15, 2026. No final broader federal rescheduling determination was identified through July 24. The catalyst has therefore moved from an active hearing to a post-hearing recommendation and final-action watch; timing and outcome remain uncertain.

July 15, 2026 — On July 13, 2026, Tilray announced it will release its fourth-quarter and full fiscal-year 2026 results (fiscal year ended May 31, 2026) after market close on Tuesday, July 28, 2026, with a webcast at 4:30 PM ET, setting the next scheduled catalyst for $TLRY. (Source: GlobeNewswire)

July 10, 2026 — On July 9, 2026, Tilray Medical announced the commercial launch of its first medical cannabis product in Panama: Tilray Oral Solution CBD100, shipped from its EU-GMP-certified facility in Portugal through a joint venture with Solana Life Group and distributed via Farmacias Arrocha under medical prescription. The move extends Tilray’s EU-GMP reach into a new regulated Latin American market, adding to a footprint of more than 20 countries. (Source: GlobeNewswire)

The most important July 1, 2026 update for Tilray Brands is not a simple marketing headline. It is a three-part setup: a new June 30 Form 8-K showing another debt-for-equity exchange, the June 29 HelloMD acquisition, and the actual start of the DEA marijuana rescheduling hearing.

The most immediate number is capital-structure related. In the June 30, 2026 Form 8-K, Tilray disclosed that between June 15, 2026 and June 24, 2026 it entered into private exchange transactions with unrelated parties, issuing 2,638,341 common shares in exchange for $12.0 million aggregate principal amount of its 5.20% Convertible Senior Notes due June 15, 2027. The shares were issued without registration under the Securities Act in reliance on Section 3(a)(9), as securities exchanged with existing security holders and with no commission or remuneration paid for soliciting the exchange.

This new filing follows the June 9 Form 8-K, where Tilray had already disclosed 1,214,186 shares issued in exchange for $6.0 million of principal amount of the same 2027 Convertible Senior Notes, plus 398,666 shares issued as partial consideration for the Lyphe Group acquisition. Looking only at the note exchanges, Tilray has now disclosed 3,852,527 shares issued in June to reduce $18.0 million of 2027 convertible-note principal. Including the Lyphe share consideration, the total number of common shares disclosed across the two recent filings rises to 4,251,193 shares.

The point is not that Tilray announced a single catastrophic dilution event. The point is that the pattern continues. Tilray’s Q3 FY2026 Form 10-Q showed 116,548,663 common shares outstanding as of March 30, 2026. Using that number only as a rough reference point, and not as an updated fully diluted calculation, the 4,251,193 shares disclosed across Lyphe consideration and the note exchanges represent about 3.6% of that share base. The debt exchanges alone represent about 3.3%. That is small enough not to rewrite the entire company story by itself, but large enough to reinforce the central issue: TLRY is managing liabilities and acquisitions partly through equity.

The second relevant update is Tilray’s acquisition of HelloMD Corporation, announced on June 29, 2026. HelloMD is a digital healthcare and patient engagement platform focused on medical cannabis education, consultations and patient support. Tilray said it was the successful bidder in HelloMD’s formal sale process and plans to acquire HelloMD’s Canadian medical cannabis assets following formal Court approval on June 29. Financial terms were not disclosed.

Industrially, HelloMD reinforces Tilray’s message that it wants to build a more integrated medical cannabis platform that is less dependent on wholesale alone. In Canada, the stated goal is to create a vertically integrated framework connecting cultivation, clinical expertise, practitioner support, product access, fulfillment and patient engagement. Tilray said HelloMD has supported hundreds of thousands of patients through telehealth consultations, educational resources and personalized medical cannabis guidance.

The bullish read-through is straightforward: Lyphe in the U.K. and HelloMD in Canada point in the same strategic direction — a more patient-facing, digital, regulated and potentially scalable medical cannabis platform. The bearish read-through is also straightforward: HelloMD’s financial terms were not disclosed, the asset comes from a formal sale process, integration still has to be proven, and the market may continue to view TLRY as a company buying platforms while issuing shares to manage debt and growth.

The third update is that the announced DEA marijuana rescheduling hearing window has ended. The process, noticed by the Federal Register and confirmed by the DEA, ran from June 29 through July 15, 2026. No final broader rescheduling action was identified through July 24. For TLRY, the remaining value is partly sector sentiment and trading attention because the stock remains one of the most liquid and recognizable cannabis proxies; the direct economic impact of any eventual outcome still has to be separated carefully from cannabis-basket price action.

On the beverage side, BrewDog confirmed that CEO James Taylor has stepped down. According to the company, BrewDog now sits under Tilray International and no longer requires a dedicated full-time CEO; Lauren Carrol remains Chief Commercial Officer and is responsible for day-to-day operations, reporting to Rajnish Ohri, President International at Tilray Brands. Tilray has said it invested about £50 million to stabilize BrewDog. The later Second Best approach does not change ownership: Irwin Simon publicly said the asset is not for sale, and no accepted offer or transaction filing has been published.

Merlintrader read-through

The July 24 setup is more precise but still delicate. Lyphe and HelloMD support an integrated medical cannabis strategy, the post-hearing federal process preserves policy optionality and BrewDog remains under Tilray control despite an unsolicited approach. The problem is that the recent 8-K filings again show the cost of the strategy: Tilray is reducing debt and buying assets, but part of the work continues to run through new shares.

03 Snapshot

Tilray Brands is one of the most visible publicly traded cannabis-linked names in North America, but the company is no longer a straightforward Canadian cannabis producer. It has evolved into a diversified consumer and regulated-products platform with operations across adult-use cannabis, medical cannabis, craft beer, spirits, beverages, hemp-based wellness and European pharmaceutical distribution.

The stock remains highly sensitive to cannabis policy headlines, especially the U.S. marijuana rescheduling process. The announced DEA hearing window ran from June 29 through July 15, 2026 and has now ended; no final broader rescheduling determination was identified through July 24. For TLRY, the remaining process matters because the stock is one of the most liquid cannabis tickers available to U.S. retail traders. The direct economic benefit of U.S. reform may be more complicated than the headline suggests, but TLRY often trades as part of the broader cannabis-policy basket.

Tilray’s business also has a second major storyline: management is trying to build a larger global consumer packaged goods platform. The March 2026 BrewDog acquisition added a globally recognized craft beer brand, UK brewing assets and a portfolio of brewpubs. That deal expands Tilray’s beverage exposure at a time when the company is trying to prove that beverage can become a durable growth engine rather than just a diversification label.

The financial picture is now a full fiscal year rather than a quarter. For fiscal 2026, ended May 31, 2026, Tilray reported record net revenue of $915.5 million, gross profit of $260.4 million and record adjusted EBITDA of $61.1 million, and guided fiscal 2027 adjusted EBITDA to $68-75 million. It ended the year with $234.6 million in cash, restricted cash and marketable securities and net debt of $0.7 million. The counterweights are equally concrete: a GAAP net loss of $105.2 million, $69.1 million of cash used in operating activities and a share count that rose roughly 24% during the year.

The core question for TLRY is whether the company can convert scale, brand recognition, cannabis optionality and beverage assets into a cleaner financial profile. The stock can move sharply on policy excitement, but a lasting rerating would require stronger evidence of margin stability, disciplined capital allocation, lower dilution risk, improving operating cash flow and successful integration of acquired beverage assets.

04 Recent operating updates — HelloMD, BrewDog, beverage and medical cannabis

The last few weeks have made Tilray more active on two fronts: integrated medical cannabis and the beverage platform. Not every update carries the same financial weight, but together they show where management wants to push the story in the second half of 2026.

The most strategic update is HelloMD. The acquisition strengthens direct-to-patient capability in Canada and adds a digital layer to medical cannabis: education, telehealth, patient engagement, practitioner support and potential demand insights. In combination with Lyphe in the United Kingdom, Tilray is building a more vertical medical cannabis profile: clinics, digital pharmacy, patient access, fulfillment and regulated supply. This is the most coherent part of the TLRY story if medical cannabis continues to normalize.

The second update concerns BrewDog. After the March deal, Tilray began using the BrewDog network to bring a selection of Tilray’s U.S. craft beer brands into the U.K. On July 17, Tilray announced a £1 million bar-tab promotion across participating Tilray-owned BrewDog pubs, running from July 20 through September 30. These initiatives are not balance-sheet catalysts by themselves, but they test whether Tilray can use BrewDog as a commercial platform rather than merely an acquired brand.

James Watt has publicly claimed that Second Best formally submitted an offer to buy BrewDog. Irwin Simon responded that BrewDog is not for sale. No signed agreement, accepted offer, SEC filing or Tilray transaction release was identified through July 24, so the approach should not be modeled as a completed or probable divestiture. The July 1 news that CEO James Taylor stepped down still makes the turnaround more delicate to monitor: BrewDog now sits inside Tilray International and no longer has a dedicated full-time CEO. The practical issue is unchanged—operating recovery, cost control, channel stabilization and economic contribution relative to fiscal 2027 expectations.

Tilray has also continued to publish beverage and spirits updates. Breckenridge Distillery, a Tilray subsidiary, announced that Rum Cask Finish earned Double Gold at the New York International Spirits Competition and that Breckenridge was named Colorado Distillery of the Year for the sixth time. That is positive for brand quality, but it should not be confused with an immediate financial catalyst. It matters as portfolio proof and brand equity, not as a standalone margin inflection.

On the Canadian cannabis beverage side, Tilray launched the Mollo Lite Blackberry Lemon Seltzers 4-Pack on August 6, the first light-THC multipack under the Mollo brand. Each 355 mL can carries 2.5 mg THC and 5 mg CBG, for 10 mg THC and 20 mg CBG per four-pack, and the product is now available through licensed cannabis retailers in select Canadian markets. It is a line extension rather than a new brand, aimed at the low-dose, sessionable segment of the THC beverage category Tilray already leads in Canada.

On the European medical cannabis side, Tilray Medical Germany’s launch of ARX™, a premium medical cannabis brand cultivated in Germany, remains relevant. Together with Lyphe and HelloMD, ARX™ strengthens the view of Tilray as an international medical cannabis operator with regulated assets in multiple markets. The key question is unchanged: can these assets become large, profitable and cash-generative enough to offset dilution, beverage complexity and cannabis-sentiment volatility?

05 Company overview

Tilray Brands, Inc. describes itself as a global lifestyle and consumer packaged goods company operating at the intersection of cannabis, beverage, wellness and entertainment. That language is broad, but it reflects the actual structure of the company today. Tilray is not only selling cannabis flower or oils in Canada. It also operates medical cannabis platforms in international markets, owns a large portfolio of beverage brands, sells wellness products and runs pharmaceutical distribution activity in Europe through Tilray Pharma.

The company’s cannabis roots remain central. Tilray and Aphria were among the most prominent names in the Canadian cannabis boom, and the combined company kept the Tilray name after the Aphria-Tilray business combination. Cannabis still defines the stock’s identity in the public market. When cannabis reform headlines hit, TLRY usually reacts as a sector proxy. When policy momentum fades, TLRY often trades with the disappointment that has followed the cannabis industry for years.

The broader business is more diversified than many retail investors realize. Tilray’s revenue is divided across cannabis, beverage, wellness and distribution. The distribution segment gives the company a less glamorous but recurring commercial base. Beverage adds consumer-brand exposure and a possible path toward a larger U.S. and global CPG platform. Wellness provides hemp-based food and consumer-health products. Medical cannabis gives Tilray a regulated, healthcare-oriented international angle.

This diversification is useful, but it also makes TLRY harder to analyze. A pure cannabis company can be judged mostly on cultivation economics, market share, regulation and cannabis margins. A beverage company can be judged on brand strength, distribution, gross margin and category growth. A pharmaceutical distributor can be judged on working capital, scale and lower-margin throughput. Tilray contains elements of all three. That can be attractive when several segments improve at the same time. It can be frustrating when investors cannot clearly see which business is supposed to drive shareholder value.

Tilray’s management has built the company around the idea that scale, brands, distribution and regulated-market access will matter when cannabis normalizes over time. The bullish view is that Tilray has survived the worst of the cannabis cycle and now owns a platform that can benefit from policy reform, international medical adoption and consumer-beverage expansion. The bearish view is that the company has become too complex, still lacks consistent GAAP profitability and continues to ask investors to value optionality before the cash flow has fully arrived.

06 History: from cannabis-market icon to diversified platform

Tilray’s stock-market history is inseparable from the cannabis boom. The original Tilray became one of the most watched cannabis stocks after its public listing, attracting intense attention during the 2018 cannabis mania. At that time, investors were pricing the sector as if legalization would create a large, fast-growing, high-margin global consumer category almost immediately. Tilray became one of the symbols of that enthusiasm.

The reality turned out to be much more difficult. Canadian legalization created a legal market, but it also exposed the sector to oversupply, price compression, limited retail rollout in some provinces, high taxes, strict advertising restrictions and intense competition. Many cannabis companies built too much capacity and spent too aggressively. As growth slowed and margins disappointed, the sector’s valuations collapsed. TLRY, like many cannabis peers, lost a large portion of the value created during the speculative boom.

The Aphria-Tilray combination marked the most important structural change in the company’s modern history. Aphria brought stronger operating discipline, a more established management team and Irwin Simon’s consumer packaged goods background. Tilray brought Nasdaq visibility, global recognition and medical cannabis infrastructure. The combined company retained the Tilray name, but the post-combination strategy became more clearly oriented toward operating scale, brand ownership, cost control, international cannabis and broader consumer packaged goods.

After the merger, Tilray continued expanding beyond cannabis. It acquired and built beverage assets in the United States, developed a portfolio of craft beer and spirits brands, and increased its emphasis on consumer experiences. The beverage strategy became a defining part of the story because cannabis reform in the United States remained uncertain. Instead of waiting only for federal legalization, Tilray moved into categories where it could operate legally today while keeping cannabis optionality alive for the future.

The reverse stock split in December 2025 was another important chapter. Tilray implemented a 1-for-10 reverse split, with shares beginning to trade on a split-adjusted basis on December 2, 2025. Mechanically, a reverse split does not change proportional ownership, but it does consolidate shares and raise the per-share trading price. In Tilray’s case, the split reduced the outstanding share count from roughly 1.16 billion shares to about 116 million shares. For many investors, the reverse split was a reminder of how far the stock had fallen since the cannabis boom years. For management, it was part of a broader effort to position the company for institutional interest, corporate flexibility and lower administrative costs.

By 2026, the company had become a different entity from the early cannabis-hype version of Tilray. It still trades as a cannabis stock, but the operating platform now includes medical cannabis, Canadian adult-use cannabis, U.S. beverages, BrewDog, hemp-based wellness and European pharmaceutical distribution. The current TLRY story is not a simple revival of the 2018 cannabis trade. It is a test of whether a damaged sector name can use scale, consumer brands and regulatory optionality to rebuild credibility.

07 DEA hearing window completed: recommendation and final action remain pending

The main sector-level catalyst attached to TLRY has moved into a post-hearing phase. According to the Federal Register notice and the DEA release, the hearing on the proposed broader rescheduling of marijuana began on June 29, 2026 at the DEA Hearing Facility in Arlington, Virginia and was required to conclude no later than July 15, 2026. Through July 29, no final broader rescheduling determination has been identified.

Two separate processes, often confused — on April 28, 2026 the Department of Justice published a final rule, effective immediately, placing FDA-approved drug products containing marijuana — and marijuana products subject to a state medical marijuana license — in Schedule III, together with an expedited federal registration process for state medical licence holders. On the same date it published the notice of hearing on the broader proposal to move marijuana itself from Schedule I to Schedule III, the process that produced the June 29 to July 15 hearing. The first action is done; the second is not.

Next procedural step — coverage of the proceeding reports that DEA Chief Administrative Law Judge Derek Julius set August 17, 2026 as the deadline for voluntary post-hearing briefs and closing arguments, after which he would issue his recommendation to the Administrator, who takes the final action. That date comes from reporting on the tribunal’s instructions rather than from a document published on DEA.gov, so it is an indicative reference rather than a confirmed agency deadline. Neither the timing of the recommendation nor the timing or content of the final action has been announced.

The proposed rule concerns the potential transfer of marijuana from Schedule I to Schedule III under the Controlled Substances Act. That distinction matters. Schedule I is the most restrictive classification and is reserved for substances considered to have no currently accepted medical use and a high potential for abuse. Schedule III would represent a materially different federal classification, potentially more favorable for medical recognition, research, compliance and sector perception.

At the same time, rescheduling is not federal legalization. It would not automatically create a fully legal national adult-use cannabis market. It would not automatically remove every conflict between state and federal law. It would not necessarily solve banking, exchange-listing, interstate-commerce or tax issues for every operator in one step. The financial impact will depend on final language, implementation, possible legal challenges, product scope and which types of operators are included.

For Tilray, the remaining catalyst is partly fundamental and partly sentiment-driven. Fundamentally, the company has medical cannabis operations, regulated international markets and experience in pharmaceutical-quality cannabis production. Market-wise, TLRY is a liquid cannabis ticker with strong retail recognition. That means it can move with the group even when the direct operating benefit is not immediately quantifiable.

This creates the familiar cannabis-stock setup: a real process, high headline sensitivity and uncertain economic translation. A favorable process can support sector sentiment; a slow, narrow or contested process can disappoint. For TLRY, the distinction between regulatory progress and earnings impact remains essential.

08 Tilray Medical, Lyphe, HelloMD and the regulated medical cannabis angle

Tilray Medical remains one of the more credible parts of the company’s cannabis narrative. In 2026, that narrative has become more concrete because Tilray added two patient-facing pieces: Lyphe Group in the United Kingdom and HelloMD in Canada. The point is not only selling cannabis product. It is controlling more parts of the medical journey, from patient education and consultations to digital pharmacy, fulfillment and regulated supply.

The Lyphe acquisition sharpens the European angle. Lyphe gives Tilray a U.K.-based medical cannabis clinic and digital pharmacy platform, rather than only a cultivation or wholesale footprint. Tilray described the deal as a step toward an integrated, patient-centric medical platform combining pharmaceutical-grade cultivation and production with clinical care, dispensing services and pharmaceutical distribution. In the U.K. medical cannabis market, where patient access, physician adoption, digital care pathways and regulated infrastructure matter, that is strategically more important than the number of shares issued as part of the consideration.

HelloMD adds a Canadian and digital component to the same strategy. Tilray described HelloMD as a digital healthcare and patient engagement platform focused on education, physician consultations and patient support. The company said the platform has supported hundreds of thousands of patients and that the acquisition should expand direct-to-patient capabilities, physician and patient education, engagement across the care journey and access in regulated markets.

This structure matters because medical cannabis tends to develop more slowly but with deeper regulatory grounding than adult-use cannabis. In medical markets, clinical trust, patient access, physician education, quality standards, reliable supply and compliance all matter. If Tilray can combine supply, clinics, pharmacy, telehealth and patient engagement, its medical platform could become more defensible than a model based only on flower or wholesale.

Tilray Medical says it operates in around 20 international markets and supplies medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments across multiple continents. The company has built EU-GMP capabilities, including facilities in Portugal and Germany, and continues to strengthen the portfolio with brands such as ARX™ in Germany. That positioning helps Tilray present itself as a regulated healthcare operator, not only as a retail cannabis stock.

The opportunity is real, but it is not automatic. European and Canadian medical cannabis markets can grow slowly because physician adoption, reimbursement, prescribing rules, patient education and national regulation all matter. A company can have strong infrastructure and still face gradual market development. For TLRY, the key metric is not the number of announcements. The key is whether medical cannabis revenue grows, whether margins remain attractive and whether Lyphe and HelloMD become relevant to consolidated results.

Medical cannabis watch

Lyphe and HelloMD improve Tilray’s strategic coherence in medical cannabis because they move the company closer to patients, clinics, telehealth and regulated access. The market will still need proof: growth, integration, margins, cash contribution and less reliance on new share issuance.

09 FY2026 and Q4 FY2026 results: record revenue, thin profitability and a beverage-driven quarter

The fiscal 2026 report is the first complete picture of Tilray as a four-segment platform with BrewDog inside the numbers. Annual net revenue of $915.5 million was a company record, and the mix shifted meaningfully: distribution drove most of the annual growth, adding $56.0 million, while cannabis added $19.3 million and beverage only $13.4 million. Beverage changes the picture only in the fourth quarter, once BrewDog is inside the numbers.

Gross profit rose 8% to $260.4 million, but gross margin slipped to 28% from 29%. Adjusted gross margin, which strips out purchase-price accounting step-up from the acquisitions, was 29% and unchanged. That gap between reported and adjusted margin is a direct consequence of buying businesses: acquisitions bring revenue immediately and margin optics later.

The fourth quarter is where BrewDog becomes visible. Beverage net revenue jumped to $105.6 million from $65.6 million a year earlier, and beverage gross profit rose to $40.6 million from $25.0 million, with margin unchanged at 38%. For the full year, beverage revenue rose only 6% to $254.0 million and beverage gross profit fell 2% to $91.2 million, with margin down to 36% from 39%. In other words: the acquisition lifted the quarterly run rate, while the underlying legacy beverage business was still under pressure for most of the year.

Distribution was the quiet engine. Net revenue rose 21% to $327.2 million and gross profit rose 39% to $40.7 million, with margin improving to 12% from 11%. The company highlighted that CC Pharma gross profit increased 57% in the fourth quarter. European pharmaceutical distribution is a low-margin business by nature, but it is also the infrastructure that carries Tilray Medical products to patients.

Cannabis grew 8% to $268.3 million with gross profit of $107.1 million and a 40% margin, unchanged year over year. International medical cannabis revenue increased 34% for the fiscal year. Wellness, the smallest segment, rose 9% to $65.9 million with a 33% margin.

Below the operating line, the story is still unfinished. Net loss was $105.2 million for the year, with a net loss per share of $1.09, which the company attributed predominantly to non-cash charges. Adjusted net income was $12.2 million, or $0.11 per share, against $6.5 million and $0.07 a year earlier. Both numbers are true; they describe different things. Adjusted profitability shows an operating business that is close to breakeven on a cash-earnings basis, while the GAAP loss and the $69.1 million of cash used in operations show that the platform is not yet self-funding.

Geographically, the 10-K shows how far the centre of gravity has moved: EMEA generated $445.7 million of fiscal 2026 net revenue, ahead of the United States at $242.4 million and Canada at $215.7 million, with $11.7 million from the rest of the world. Europe is now the largest revenue region for a company that most U.S. retail traders still treat as a Canadian cannabis stock.

10 Q3 FY2026 in context: the quarter before BrewDog entered the numbers

Tilray’s Q3 FY2026 results provide the clearest recent operating snapshot. For the quarter ended February 28, 2026, the company reported net revenue of $206.7 million, up 11% from $185.8 million in the prior-year period. Gross profit increased 6% to $55.0 million, while gross margin was 27%, compared with 28% in the prior-year period. Adjusted EBITDA increased 19% to $10.7 million.

Cannabis was one of the stronger parts of the quarter. Cannabis net revenue increased 19% to $64.8 million, driven by a 73% increase in international cannabis revenue and an 8% increase in combined Canadian adult-use and medical cannabis net revenue. Cannabis gross profit increased 18% to $26.0 million, and cannabis gross margin was 40%. For a company still strongly associated with cannabis, those numbers are important because they show that the cannabis segment is not only a legacy narrative.

Distribution also contributed meaningfully. Distribution net revenue, which includes Tilray Pharma, grew to a third-quarter record of $83.0 million, compared with $61.5 million in the prior-year period. Distribution gross profit increased to $10.0 million, and gross margin improved to 12% from 9%. Distribution is less exciting than rescheduling headlines, but it can support the revenue base and help stabilize the company’s broader financial profile.

Wellness remained smaller but positive. Wellness net revenue increased 16% to $16.4 million, and wellness gross profit increased 19% to $5.4 million. Gross margin improved to 33%. This segment is not the reason most traders focus on TLRY, but it fits management’s broader consumer and wellness strategy.

Beverage was the weak point. Beverage net revenue fell to $42.6 million from $55.9 million. Beverage gross profit fell to $13.6 million from $19.9 million, and beverage gross margin declined to 32% from 36%. This weakness matters because beverage is no longer a small side story. Tilray is actively building a major beverage platform. The company has to show that beverage can recover, integrate BrewDog and become a contributor to profitability rather than just a revenue-expansion vehicle.

The bottom line improved compared with the impairment-heavy prior-year period, but Tilray still reported a GAAP net loss of $25.2 million in Q3 FY2026. The prior-year quarter had included a much larger net loss of $793.5 million. Adjusted cash operating income improved to $4.0 million compared with an adjusted cash operating loss of $3.1 million in the prior-year quarter. Those improvements are relevant, but the company still has to bridge the gap between adjusted metrics and clean, durable cash generation.

11 Balance sheet, capital structure and dilution watch

Updated after the FY2026 report — Tilray ended fiscal 2026 with approximately $234.6 million in cash, restricted cash and marketable securities and net debt of $0.7 million, against total assets of $2.33 billion and total stockholders’ equity of $1.59 billion. Balance-sheet debt at May 31, 2026 consisted of $8.8 million of bank indebtedness, $18.2 million of current long-term debt, $120.4 million of long-term debt and $79.5 million of convertible debentures at carrying value.

How the equity was used — the 10-K quantifies the dilution mechanics for the year. Under the previous $250 million at-the-market program, completed in the quarter ended November 30, 2025, Tilray issued 6,777,224 shares for $74.7 million of gross proceeds. Under a new $180 million ATM program signed on April 15, 2026 with Jefferies, TD Securities and Roth Capital, the company issued 12,848,281 shares for $87.0 million of gross proceeds at an average price of $6.77 per share, with a substantial portion sold on April 22 and 23, 2026 during the trading surge that followed U.S. rescheduling developments. Across both programs Tilray issued 19,625,505 shares for $161.6 million of gross proceeds in fiscal 2026, and a further 639,581 shares for $3.5 million between June 1 and June 4, 2026. On those disclosed figures, roughly $89.5 million of the new ATM authorization remains available.

What that means in plain terms — management sold stock into strength during a policy-driven rally and used shares to retire convertible debt. That is defensible capital management, and it is why net debt is now close to zero. It is also the reason the share count rose from 106.1 million to 131.7 million during the fiscal year and to 136.2 million by July 24, 2026. Shareholders received a stronger balance sheet and paid for it with ownership.

Remaining 2027 maturity — $70.0 million of principal remains on the 5.20% Convertible Senior Notes due June 15, 2027 as of the 10-K filing date, and management stated it intends to continue to opportunistically purchase or exchange equity for those notes before maturity, subject to market conditions. On the July 24 Sixth Amendment, the revolving commitment at American Beverage Crafts Group was reduced from $25.0 million to $15.0 million with modified covenants.

Earlier in the year, Tilray ended Q3 FY2026 with $264.8 million in cash, restricted cash and marketable securities. Management also highlighted a net cash position of $3.5 million, improved by $40.2 million from a net debt position of $36.6 million in the prior-year period. The company said it reduced total outstanding debt by $4.2 million during the quarter.

This balance sheet position is one reason Tilray remains more visible than many weaker cannabis peers. Cash gives management room to integrate acquisitions, invest in product launches, manage working capital and pursue strategic opportunities. A net cash position, even a modest one, is better than a capital structure dominated by immediate balance-sheet pressure.

That said, TLRY is not a risk-free balance-sheet story. Cannabis companies have a long history of dilution, impairments and capital-market dependence. Tilray’s reverse split reduced the share count but did not erase the historical dilution issue. The company still has to show that future growth can be funded through operating performance rather than repeated shareholder dilution.

The two June 2026 Form 8-K filings make the dilution watch more concrete. The first filing disclosed 1,214,186 shares issued to reduce $6.0 million of 2027 Convertible Senior Notes and 398,666 shares issued as part of the Lyphe consideration. The second filing, signed on June 30, disclosed another 2,638,341 shares issued in exchange for $12.0 million of principal amount of the same notes. In total, Tilray has disclosed 3,852,527 shares to reduce $18.0 million of convertible debt, plus 398,666 shares for Lyphe.

From a corporate-finance perspective, the exchanges have a logic: they reduce 2027 debt without using immediate cash. From a common-shareholder perspective, they still increase the share count. That is the central tension in TLRY. Management can argue that it is reducing liabilities and building medical cannabis platforms; the market can respond by asking how much that costs in dilution, cash flow and complexity.

The reverse split remains important for market perception. Tilray’s 1-for-10 reverse stock split became effective in December 2025, with split-adjusted trading beginning on December 2, 2025. The company said the split would reduce outstanding shares from approximately 1.16 billion to approximately 116 million. A reverse split can help with listing requirements, optics and administrative costs, but for many investors it also reflects significant prior share-price weakness.

A sustainable recovery would require more than a cleaner share count. It would require better operating results, cash conversion, disciplined BrewDog integration, measurable contribution from Lyphe and HelloMD and, most importantly, confidence that additional exchanges, ATM usage or share issuance will not become the normal mechanism for funding the strategy.

12 BrewDog and the beverage strategy

September 1, 2026 — BrewDog launches Liquid Visions across UK grocery. Tilray announced a four-beer premium craft series rolling out from this week through October. Dive Bar, a 6% ABV Sunshine IPA, and Krush Test Dummy, an 8% ABV Double Hazy IPA, open the range. Pacific Parallax, a 6.3% ABV double dry-hopped New Zealand Pale Ale, follows in late September as a Sainsbury’s exclusive, and Strange Bines, a 7% ABV Saturated IPA, in October. The first cans reach Tesco this week, with a second wave from September 21 and distribution across the major UK grocers. Each 440ml can is brewed with 26 grams of hops per litre, and the artwork on each is commissioned from a different illustrator. Rajnish Ohri, President International at Tilray Brands, is the executive quoted, framing the launch as part of the international beverage strategy and as a follow-on to the World Beer Awards results below. No revenue, volume, listing count or shelf-space figure is attached to the release, and no Form 8-K accompanied it as of September 1, 2026, so this is a distribution event inside the beverage segment rather than anything that moves the FY2027 guidance in section 09 or the approximately $200 million of annual net revenue the company attributed to the acquired BrewDog assets. Source: company release, September 1, 2026.

August 25, 2026 — BrewDog at the World Beer Awards. Hazy Jane, Wingman and Mackie’s Two Scoops took gold and a Scotland Country Winner award, with Punk IPA, Lost Lager, Black Heart and Mello also recognised. It is brand recognition, not a financial event: no revenue, volume or contract figure is attached, and it belongs in the beverage story rather than in the numbers.

The BrewDog acquisition is the biggest non-cannabis development in Tilray’s 2026 story. On March 2, 2026, Tilray announced the acquisition of selected BrewDog assets, including the global brand, worldwide intellectual property, UK brewing operations and 11 strategic brewpubs in the United Kingdom and Ireland. Tilray stated that it paid £33 million and expected the acquired assets to generate approximately $200 million in annual net revenue and $6 million to $8 million of adjusted EBITDA in fiscal 2027.

The deal is central to Tilray’s goal of building a global beverage platform. Management said the acquisition could help expand Tilray’s total beverage platform to approximately $500 million in annual revenue and support annualized consolidated revenue of about $1.2 billion. BrewDog brings a globally recognized craft beer brand, brewing capacity outside the United States, an international distribution network and hospitality assets.

The strategic logic is visible. Tilray already owns U.S. beverage brands such as SweetWater, Montauk Brewing, Alpine, Green Flash, Blue Point, 10 Barrel, Widmer Brothers, Redhook, Shock Top and Breckenridge Distillery. BrewDog adds a stronger international bridge. If Tilray can use BrewDog’s network to distribute its U.S. brands internationally and use its existing infrastructure to refresh BrewDog, the beverage segment could become a more meaningful part of the company.

The risk is also visible. BrewDog came to Tilray after a difficult period for the brand. Acquiring assets at a distressed or strategic price can create value, but only if integration works. Tilray must stabilize operations, support the brand, manage costs, protect margins and avoid turning beverage into a distraction from cannabis and cash-flow discipline.

The Q3 FY2026 beverage decline makes the BrewDog execution test more important. Beverage revenue was down year over year before BrewDog’s results were reflected in the quarter. That means Tilray’s next beverage reports will be judged closely. Investors will look for signs that BrewDog can add revenue without dragging margins, that legacy beverage brands are stabilizing and that the company can generate the projected adjusted EBITDA contribution in fiscal 2027.

Beverage watch

BrewDog can strengthen Tilray’s consumer platform, but it also raises the execution bar. The key is not the size of the acquired brand alone. The key is whether beverage revenue, margins and cash contribution improve after integration.

13 Cannabis Canada and international growth

Canada remains a foundational market for Tilray. It is federally legal, it gives the company operational scale and it remains part of the company’s brand identity. In Q3 FY2026, Tilray reported an 8% increase in combined Canadian adult-use and medical cannabis net revenue. The company has also described itself as holding a leading market position in Canada by cannabis revenue.

The Canadian market is mature and competitive. Price pressure, provincial distribution systems, excise taxes, product-category shifts and retail fragmentation all affect operator performance. Growth in Canada is not enough by itself if it comes at the expense of margin. For TLRY, the healthier signal is cannabis gross margin, which stood at 40% in Q3 FY2026.

International cannabis is the more dynamic part of the cannabis segment. Tilray reported 73% growth in international cannabis revenue in Q3 FY2026. That growth supports the company’s long-running argument that global medical cannabis can become a meaningful business. International markets can offer more regulated, medically oriented pathways than the adult-use market, but they also require patience, compliance and country-by-country execution.

The international opportunity is not limited to one country. Tilray Medical has described a platform spanning more than 20 regulated international markets and five continents. Its European infrastructure, including Portugal and Germany, gives the company a base for pharmaceutical-quality supply. The key issue is whether this platform can become large enough to offset volatility in other segments and justify a higher-quality valuation multiple.

Canada provides the operating base. International medical cannabis provides the growth angle. U.S. policy provides the sentiment catalyst. TLRY’s cannabis thesis depends on all three, but each works differently. Investors should avoid treating every cannabis headline as equal. A Canadian market-share update, a German medical access development and a U.S. rescheduling hearing can all matter, but they affect Tilray in different ways and on different timelines.

14 Management and leadership

Irwin D. Simon is Chairman, President and Chief Executive Officer of Tilray Brands. His background helps explain the direction of the company. Simon is a consumer packaged goods executive with a history of building and scaling branded businesses. Before Tilray, he founded and led The Hain Celestial Group, a natural and organic products company, and he has also been involved with Whole Earth Brands.

This background is important because Tilray’s strategy is not built only around cultivation. It is built around brands, distribution, acquisitions, category adjacency and consumer platforms. Simon’s approach is visible in the Aphria-Tilray combination, the beverage acquisitions, the BrewDog deal, the Lyphe acquisition and the company’s repeated emphasis on becoming a global lifestyle and CPG platform.

The strength of this approach is that Tilray is not waiting passively for U.S. cannabis legalization. The company is building legal revenue streams in beverage, distribution and wellness while maintaining cannabis optionality. The weakness is that the strategy requires excellent capital allocation. Acquisitions can create scale, but they can also add complexity. A platform can become powerful, but it can also become difficult to value if the market cannot see clear cash generation.

Management’s credibility will likely be judged on several measurable items: achieving fiscal 2026 adjusted EBITDA guidance, integrating BrewDog without margin damage, preserving balance-sheet flexibility, improving operating cash flow, limiting dilution and showing that cannabis growth is not offset by weakness in beverage or other segments. In a stock like TLRY, communication matters, but numbers matter more.

15 Institutional ownership, analyst perception and trading profile

TLRY remains a high-visibility retail and thematic stock. Institutional ownership is not comparable to mature large-cap consumer companies, partly because cannabis remains a difficult sector for many institutions. Regulatory uncertainty, historical dilution, uneven profitability and the long collapse in cannabis valuations have kept many investors cautious.

The stock’s trading profile is shaped by liquidity, name recognition and policy sensitivity. TLRY often attracts attention during cannabis-sector rallies because it is accessible, widely recognized and listed on major exchanges. That visibility can be valuable when sentiment improves. It can also amplify downside volatility when the cannabis tape weakens.

Analyst perception tends to revolve around the same questions that define the company: cannabis policy, adjusted EBITDA, beverage integration, cash flow, dilution and whether the diversified model deserves a better valuation. Price targets should be treated carefully because reverse splits, stale models and different assumptions around rescheduling can create wide dispersion. The more useful signal is the language analysts use after earnings and policy updates.

If analysts begin describing Tilray as a credible consumer-platform turnaround with improving cash quality, the stock could attract a different type of investor attention. If coverage continues to focus on dilution, GAAP losses, policy uncertainty and segment complexity, TLRY may remain primarily a momentum and policy-trading vehicle.

16 Retail sentiment

Retail sentiment remains a major part of the TLRY setup. On Stocktwits, Reddit and X, the stock tends to attract traders focused on cannabis reform, Schedule III, reverse-split psychology, short interest, meme-stock style moves and the memory of past cannabis rallies. This attention can create sharp moves when the sector turns active.

The bullish retail narrative is straightforward: cannabis reform is moving, TLRY is one of the most recognizable tickers in the group, the company has a global platform, the Lyphe deal strengthens European medical cannabis, the reverse split cleaned up the share count and any positive rescheduling signal could bring speculative capital back into cannabis equities.

The bearish retail narrative is also straightforward: TLRY has disappointed shareholders for years, cannabis policy has repeatedly failed to deliver clean upside, the reverse split reflects prior weakness, dilution remains a concern, the latest 8-K again shows equity being used as currency and the company’s diversification may make the story less focused. Bears also point to GAAP losses and the recent beverage decline.

Retail sentiment is useful as a gauge of attention, not as proof. TLRY can move quickly when attention builds, but sentiment alone cannot repair margins, complete an integration or produce cash flow. The stock’s social visibility makes it tradable and dangerous at the same time.

17 Index inclusion and passive-flow watch

Tilray’s liquidity, exchange listing and thematic relevance keep it visible to cannabis ETFs and sector-focused funds. The reverse split also gives the stock a cleaner per-share structure than the pre-split billion-share count. That said, broad index inclusion should not be treated as a confirmed catalyst unless a specific index provider announces it.

The more realistic watch item is thematic and passive exposure around cannabis policy. If the rescheduling process improves sentiment and market capitalization recovers, cannabis-linked ETFs and thematic portfolios may adjust exposure. If liquidity remains strong and TLRY continues to appear on retail and institutional screens, passive and thematic flow could matter around policy windows.

This is a scenario to monitor, not a fact to price as guaranteed. Index eligibility depends on market cap, float, liquidity, domicile, exchange rules and specific index methodology. TLRY may be worth monitoring for passive-flow sensitivity, but the primary catalysts remain policy, earnings, cash flow and BrewDog integration.

18 Bull case

The bull case begins with cannabis policy. If the June 29 DEA hearing process moves toward broader Schedule III rescheduling, cannabis equities could attract renewed attention. TLRY’s liquidity and brand recognition make it a natural candidate for traders seeking exposure to the theme. Even if the direct benefits are not perfectly aligned with Tilray’s operating footprint, sector sentiment could still support the stock.

The second pillar is cannabis segment performance. Q3 FY2026 showed 19% cannabis revenue growth, 73% international cannabis growth and 40% cannabis gross margin. If Tilray can maintain strong international cannabis momentum while stabilizing Canada, the market may begin to assign more value to the cannabis business itself rather than treating it as only a policy option.

The third pillar is the Lyphe acquisition and European medical cannabis infrastructure. Lyphe gives Tilray a patient-facing U.K. platform, not just another cultivation or wholesale asset. If the company can integrate clinic, pharmacy, distribution and medical cannabis supply into a scalable model, the deal could strengthen Tilray’s international medical cannabis credibility and provide an additional path to regulated growth.

The fourth pillar is BrewDog and beverage recovery. If BrewDog contributes close to management’s fiscal 2027 expectations, expands distribution and helps Tilray build a roughly $500 million beverage platform, the company’s CPG strategy becomes more credible. A successful beverage integration would also reduce dependence on cannabis policy headlines.

The fifth pillar is financial discipline. If adjusted EBITDA guidance is achieved, operating cash flow improves and dilution stays controlled, TLRY could gradually rebuild trust. The market does not need Tilray to become perfect overnight. It needs proof that the company is moving from story equity toward a more durable operating model.

19 Bear case and red flags

The bear case starts with policy disappointment. Cannabis stocks have repeatedly rallied on reform expectations and then sold off when timelines stretched, details disappointed or political momentum faded. If the post-hearing DEA process produces limited progress, delays, confusion or a scope perceived as too narrow, TLRY could trade lower even if company-specific fundamentals are unchanged.

The second red flag is dilution. The new June 30 8-K comes only weeks after the prior June filing and brings the total disclosed debt-for-equity exchanges to $18.0 million of 2027 principal for 3,852,527 shares. The market could read that sequence not as orderly cleanup, but as confirmation that Tilray still needs equity to manage liabilities and strategy.

The third red flag is profitability. Tilray’s adjusted EBITDA improved, but the company still reported a GAAP net loss in Q3 FY2026. Adjusted metrics can be useful, but the market eventually wants durable operating cash flow and cleaner earnings. If losses persist and cash generation does not improve enough, the valuation argument weakens.

The fourth red flag is beverage execution. BrewDog could be a smart acquisition, but it requires capital, management focus and integration. James Taylor’s exit is not automatically negative, but it confirms that the asset is being reorganized under Tilray International. If beverage numbers remain weak or BrewDog requires more cash than expected, the consumer-platform thesis could lose credibility.

The fifth red flag is medical cannabis integration. Lyphe and HelloMD make the story more coherent, but patient-facing assets need to generate measurable results. If they remain mostly strategic announcements without visible contribution to revenue, margins or cash flow, the market may treat them as additional acquisition complexity.

The sixth red flag is complexity. Tilray now has cannabis, medical cannabis, pharmaceutical distribution, beverage, spirits, wellness, BrewDog and digital platforms. Diversification can help, but too much complexity can reduce confidence if management cannot clearly show how the pieces create value for common shareholders.

20 Bull, base and bear scenarios

Bull case

Rescheduling momentum improves, international cannabis continues growing, Lyphe strengthens the U.K. medical platform, Canada remains stable, BrewDog integration performs well, beverage margins recover and adjusted EBITDA guidance is achieved. TLRY begins to trade less like a damaged cannabis relic and more like a cannabis-linked consumer turnaround.

Base case

Policy progress remains real but slow, cannabis results stay constructive, beverage needs more time and cash flow improves gradually. The stock remains catalyst-sensitive, with rallies and pullbacks around news rather than a clean long-term rerating.

Bear case

The DEA process disappoints, beverage integration underwhelms, Lyphe does not become accretive quickly enough, losses persist, dilution concerns return and cannabis sentiment fades. TLRY remains volatile but fails to rebuild durable investor trust.

21 What to monitor next

• DEA post-hearing process: the June 29-July 15 hearing window has ended; reporting points to August 17, 2026 for voluntary post-hearing briefs, followed by the judge’s recommendation and final action by the Administrator. Timing, scope and legal challenges all remain open.
• FY2027 guidance execution: whether adjusted EBITDA lands inside the $68-75 million band and whether revenue clears the $1 billion mark management referenced.
• Operating cash flow: the single most important number for this story. Fiscal 2026 used $69.1 million of cash in operations; the gap to adjusted EBITDA has to narrow.
• Share count and ATM: 136,203,579 shares were outstanding on July 24, 2026 and roughly $89.5 million of the April 2026 ATM authorization appears unused; watch how much of it is drawn and at what prices.
• 2027 debt: $70.0 million of principal remains on the 5.20% Convertible Senior Notes due June 15, 2027, and management has said it intends to keep exchanging equity for them opportunistically.
• Credit facility: after the July 24 Sixth Amendment cut the revolver from $25.0 million to $15.0 million, monitor covenant headroom and any further amendments.
• HelloMD: integration of Canadian assets, partnership continuity, patient-access contribution and potential direct-to-patient revenue impact.
• Lyphe: evidence that the U.K. clinic and digital pharmacy platform can become accretive in 2027 as management expects.
• Q1 FY2027 results: the first quarter ending August 31, 2026 is the first test of the new guidance and the first full quarter of BrewDog with a clean comparison base; Tilray has historically reported that quarter in early October.
• BrewDog: Tilray management has said the business is not for sale and no transaction has been announced; monitor the CEO transition, role of Tilray International, operating stabilization and fiscal 2027 economic contribution.
• Beverage economics: Q4 beverage revenue jumped to $105.6 million with BrewDog inside the numbers, while full-year beverage gross profit still fell 2%. Watch whether the acquired revenue converts into segment profit growth.
• International cannabis: international medical cannabis revenue grew 34% in fiscal 2026 and EMEA is now the largest revenue region at $445.7 million; watch whether that pace holds against a bigger base.
• Retail sentiment: Stocktwits, Reddit and X can amplify moves around cannabis-policy headlines, but they do not replace cash flow and execution.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

22 Bottom line

Tilray Brands is one of the most complicated names in the cannabis group. It has real revenue, real assets, a large public profile, international medical cannabis infrastructure, a growing beverage platform and a defined policy catalyst. It also has a difficult history, a reverse split, persistent GAAP losses, dilution concerns and a business model that remains harder to value than a pure cannabis, beverage or distribution company.

The fiscal 2026 report sharpens rather than resolves that complexity. Revenue, adjusted EBITDA and the balance sheet all improved, and net debt is effectively gone. But the improvement was funded in large part by issuing stock: 19.6 million shares through at-the-market programs during the year, plus 3.9 million more in June to retire convertible notes. Operations still consumed $69.1 million of cash. A company that turns equity into a clean balance sheet has bought time; it has not yet proved it can fund itself.

The newest filings make the mechanics explicit. Tilray used shares to complete acquisitions and to reduce 2027 convertible-note debt to $70.0 million of remaining principal. That is not automatically negative — it preserves cash, reduces liabilities and strengthened the European medical cannabis platform, now the largest revenue region. But it keeps capital structure, dilution and execution discipline as central to the TLRY case as any cannabis-reform headline.

The company-specific test is now the fiscal 2027 guidance of $68-75 million in adjusted EBITDA and the management expectation of over $1 billion in revenue, with the first checkpoint at the quarter ending August 31, 2026. The policy process runs in parallel and on its own clock: the April 2026 final rule already moved FDA-approved and state-licensed medical marijuana products to Schedule III, while the broader rescheduling of marijuana itself is still in the post-hearing phase with no announced timeline.

The stock is best understood as a high-volatility cannabis-linked turnaround platform. The story is alive, but it still has to be proven through execution, cash flow, disciplined capital allocation and segment-level improvement.